Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20272357 | 0.91 | MGLL (0.48) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL16475733 | 0.91 | MGLL (0.48) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL11890622 | 0.89 | MGLL (0.49) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL16475721 | 0.89 | MGLL (0.49) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL30986864 | 0.85 | MGLL (0.56) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL9846659 | 0.84 | MGLL (0.62) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL21777065 | 0.84 | MGLL (0.62) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL21433889 | 0.84 | MGLL (0.62) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL21433779 | 0.84 | MGLL (0.62) | MAPTL3MBTL1MGLLCRHBPCRHR2 | |
| SCHEMBL2234364 | 0.84 | MGLL (0.62) | MAPTL3MBTL1MGLLCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3202760-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2663548-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | LIPG, EGFR, LDLR | MAPT 1781/4885L3MBTL1 2467/4885MGLL 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.